Physician profile
Eduardo Parra Davila
NPI 1609864925
$577,095.24
in general payments reported to CMS, 2019-2025
25 companies · $114K in 2025
The $114K reported for 2025 was more than what 99% of Colon & Rectal Surgery providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $106K · 2020: $62K · 2021: $19K · 2022: $103K · 2023: $119K · 2024: $55K · 2025: $114K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $139K · Travel and Lodging: $70K · Honoraria: $50K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $17K · Food and Beverage: $7,583 · Education: $3,750.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $138,984.60 |
| Travel and Lodging | $70,381.28 |
| Honoraria | $50,365.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $16,500.00 |
| Food and Beverage | $7,582.94 |
| Education | $3,750.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon INC. | $237,964.23 | 2019-2025 | Endopath, Harmonic, Monarch Platform |
| Davol INC. | $186,428.60 | 2019-2025 | Phasix Mesh, Bard Mesh |
| Intuitive Surgical, INC. | $47,626.37 | 2019-2025 | Da Vinci Sp, Da Vinci Surgical System |
| Sysmex America, INC. | $41,603.47 | 2025 | Hinotori |
| Momentis Surgical INC. | $27,192.73 | 2022-2025 | Anovo Surgical System |
| Stryker Corporation | $17,354.91 | 2025 | 1788 |
| Medtronic, INC. | $13,695.74 | 2021-2025 | Manoscan, Endoflip |
| Medical Device Business Services, INC. | $2,246.74 | 2025 | |
| Tela Bio, INC. | $576.37 | 2024-2025 | Ovitex 2s, Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Acera Surgical, INC. | $426.80 | 2024-2025 | Restrata Wound Matrix |
| Karl Storz Endoscopy-America | $416.07 | 2019-2023 | Image1 S Connect |
| Activ Surgical, INC. | $401.24 | 2024-2025 | Activsight |
| Covidien Lp | $366.34 | 2019-2020 | |
| Kerecis Limited | $272.07 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Becton, Dickinson and Company | $133.32 | 2024-2025 | Phasix Mesh |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $117.64 | 2025 | Perclot |
| Conmed Corporation | $80.00 | 2019 | |
| Merit Medical Systems INC | $62.03 | 2025 | Esophyx |
| Cook Medical LLC | $46.54 | 2022 | |
| Medicaroid, INC. | $21.07 | 2024 | |
| Cumberland Pharmaceuticals, INC. | $16.81 | 2021 | |
| Lsi Solutions INC | $16.59 | 2023 | Fornisee |
| Sirtex Medical INC | $14.93 | 2020 | |
| Enterra Medical, INC. | $14.63 | 2024 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eduardo Parra Davila listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.